TransMedics Group, Inc. $TMDX Shares Sold by Montanaro Asset Management Ltd

Montanaro Asset Management Ltd trimmed its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 21.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101,939 shares of the company’s stock after selling 28,647 shares during the quarter. TransMedics Group comprises 3.5% of Montanaro Asset Management Ltd’s portfolio, making the stock its 11th largest holding. Montanaro Asset Management Ltd owned about 0.30% of TransMedics Group worth $12,401,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Harvest Fund Management Co. Ltd acquired a new position in TransMedics Group during the 3rd quarter worth $29,000. Optiver Holding B.V. increased its holdings in shares of TransMedics Group by 248.1% during the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock valued at $30,000 after purchasing an additional 191 shares during the period. Allworth Financial LP raised its stake in shares of TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares in the last quarter. LOM Asset Management Ltd bought a new stake in shares of TransMedics Group during the third quarter valued at about $34,000. Finally, FNY Investment Advisers LLC acquired a new stake in TransMedics Group in the third quarter worth about $34,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TMDX has been the topic of a number of recent analyst reports. Oppenheimer downgraded shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Piper Sandler decreased their price objective on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a research note on Tuesday, June 9th. Wall Street Zen downgraded TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, TD Cowen decreased their price target on TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Hold” and an average price target of $134.50.

TransMedics Group Stock Performance

Shares of TMDX opened at $78.79 on Friday. The firm’s 50 day moving average is $83.39 and its 200-day moving average is $112.79. The stock has a market capitalization of $2.72 billion, a P/E ratio of 17.91 and a beta of 1.91. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19. TransMedics Group, Inc. has a 12-month low of $60.10 and a 12-month high of $156.00.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The business had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.70 earnings per share. Equities research analysts anticipate that TransMedics Group, Inc. will post 1.98 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director owned 16,642 shares in the company, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.